Know Labs, Inc. (KNW) - גידול ברווח למניה בשנה הנוכחית

Know Labs, Inc. (KNW) develops automated AI systems for non-invasive glucose monitoring, reducing the workload for physicians. The annual EPS volatility reflects current yield dynamics, where 0.00 serves as the current parameter value. The company currently relies on investment due to testing stages and FDA approval; however, commercial success will grant it total pricing power within the diabetic device segment.

This indicator measures the year-over-year dynamics of earnings per share, filtering out market noise to assess the actual rate of capital growth. By analyzing the annual growth of earnings per share, an investor can see the lack of a commercial base for Know Labs, Inc. (KNW), as the business is entirely dependent on FDA approval. Such high speculation regarding cash inflows makes the company's current development model extremely risky.